Hi friend,

Headspace announced partnerships with multiple speciality care providers, Headstream announced its 2026 Residency cohort, Bill Ackman is opening a Brain Research Institute, and Otsuka received FDA approval for an interesting new ADHD drug.

It was also a fascinating week on the research front. A Swedish study added to the evidence base for GLP-1s in behavioural health, Medicaid managed care consolidation was found to be associated with worse mental health care, and Kenyan researchers showed that LLMs can automatically monitor therapy session fidelity in multilingual, low-resource settings.

A busy week, but as always, I’m here to tell you everything you need to know about what’s happening in mental health innovation.

So let’s get into it.

These weekly emails give you an easy way to stay on top of everything that’s happening and to understand its implications. If you find them valuable, consider joining the 500 other mental health leaders who are Hemingway Pro members. As a Pro Member, you get access to deep industry insights, access to our private Slack group and invites to our member-only events. You will also be supporting our work.